<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724501</url>
  </required_header>
  <id_info>
    <org_study_id>UHN REB 01-0256-C</org_study_id>
    <secondary_id>Terry Fox Grant #11425</secondary_id>
    <nct_id>NCT02724501</nct_id>
  </id_info>
  <brief_title>Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer</brief_title>
  <official_title>Clinical and Molecular Studies of the Tumour Suppressor Gene PTEN in Endometrioid Type Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project seeks to understand the role of the PTEN tumour suppressor gene in endometrial&#xD;
      cancer (tumours of the uterine lining), the most common gynecologic cancer in the developed&#xD;
      world. The studies in this program span the spectrum from fruit flies to humans, as part of a&#xD;
      synergistic partnership that will significantly enhance our understanding of the molecular&#xD;
      genetic events involved in the development and progression of endometrial cancer. The&#xD;
      discovery of new targets for therapy, and the ability to evaluate these in subsequent&#xD;
      clinical trials is a significant strength of this scientific interaction, which may result in&#xD;
      cures for patients with primary and relapse endometrial cancer and prevention of this cancer&#xD;
      in women who are at high risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PTEN is a critical module that regulates effects of sex hormones on the growth and apoptosis&#xD;
      of endometrial cells; and plays an important role in the pathogenesis of subgroups of&#xD;
      endometrial cancers, their biologic behaviour and responses to therapeutic agents.&#xD;
      Furthermore, mutational inactivation of the PTEN gene can serve as an independent molecular&#xD;
      marker that can predict relapse and survival in endometrial cancer. The prognostic effects of&#xD;
      PTEN may also be modulated by other tumour suppressor gene losses including P53 mutations, by&#xD;
      hormone receptor status, and microsatellite instability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of endometrial cancer patients with inactivated PTEN tumor suppressor gene</measure>
    <time_frame>6 months</time_frame>
    <description>Determining the association of PTEN inactivation and PKB expression, mutation of p53, microsatellite instability and progesterone receptor status in endometrial cancer</description>
  </primary_outcome>
  <enrollment type="Actual">217</enrollment>
  <condition>Endometrial Neoplasms</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>Using questionnaire to obtain patient's medical and family history of cancer.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample-DNA testing / Tumour-genetic markers</intervention_name>
    <description>Using Samples obtained to produce summary statistics on the tumour markers</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Endometrial Cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 and older&#xD;
&#xD;
          -  patients who had a hysterectomy&#xD;
&#xD;
          -  patient able to provide consent and complete questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Fyles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

